Toronto-based AI company Cohere has acquired Reliant AI, a biopharmaceutical data processing startup with roots in Germany and Canada, marking its second acquisition in a month and expanding its footprint in healthcare and life sciences globally.
- Acquisition strengthens Cohere’s healthcare AI capabilities.
- Reliant AI’s team and technology join Cohere’s flagship platform.
- Deal expands Cohere’s presence in Canada, Germany, and global pharma.
What happened
Cohere announced the acquisition of Reliant AI, a startup specializing in biopharmaceutical data processing with teams based in Montréal and Berlin. This is Cohere’s second acquisition after it announced a planned takeover of German AI firm Aleph Alpha earlier in April. Reliant AI was founded in 2019 by former Google researchers and raised roughly $18.4 million CAD by 2024. Financial details of the deal have not been disclosed.
The acquisition brings Reliant AI’s proprietary biomedical datasets, research team, and domain-optimized technology into Cohere’s enterprise AI product, North. This integration is expected to accelerate drug discovery and clinical development services under North for Pharma, broadening Cohere’s specialization in healthcare and life sciences.
Why it matters
Healthcare is one of the most consequential sectors for AI application due to its demand for secure, specialized, and sovereign systems. Cohere’s CEO emphasized this area as a key growth opportunity, positioning the acquisition as essential for enhancing AI-driven solutions tailored to healthcare challenges.
In a market where AI consolidation is reducing non-US options, Cohere aims to stand out by focusing on data privacy and regulatory compliance. The deal also extends Cohere’s geographic reach, leveraging shared Canadian and German ties to serve a global healthcare customer base including major pharmaceutical companies like GSK and Ipsen.
What to watch next
Cohere will integrate Reliant AI’s team of over 30 employees across its new healthcare AI offerings. Key leaders from Reliant AI will take on senior roles in Cohere’s AI verticalization and modeling divisions, highlighting a focus on building industry-specific AI capacity.
The market will be watching how Cohere develops North for Pharma as part of its expanding industry portfolio, potentially accelerating research innovation and reducing the time to market for new therapeutics. Cohere’s ability to capitalize on sovereign, secure AI could influence competitive dynamics in the global healthcare technology space.